Back to search

Article

Intrathecal pemetrexed in patients with EGFR-TKI resistant refractory leptomeningeal metastasis lung adenocarcinoma : a retrospective study

2023-12-06

Abstract excerpt

<title>Abstract</title><p>The incidence of meningeal metastasis in lung adenocarcinoma with EGFR mutation is increasing annually. Refractory meningeal metastasis following EGFR-TKI resistance has no effective treatment and a lethal complication of tumors. The purpose of this study was to evaluate the potential antitumor efficacy and safety of intrathecal pemetrexed in patients with EGFR-TKI resistance refractory m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8384b1ac-e755-58f9-b11a-61ee45704f84
DOI
10.21203/rs.3.rs-3690139/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Intrathecal pemetrexed in patients with EGFR-TKI resistant refractory leptomeningeal metastasis lung adenocarcinoma : a retrospective studyDOI 10.21203/rs.3.rs-3690139/v1
Combined Furmonertinib and Intrathecal Chemotherapy for Leptomeningeal Metastasis from Non-Small Cell Lung Cancer: Efficacy, Safety, and CSF Drug ConcentrationsSemantic proximity
Real-world survival of EGFR-mutated NSCLC with leptomeningeal metastases: prognostic impact of TKIs and local multidisciplinary treatment from the CLM-tree registrySemantic proximity
[Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis].Semantic proximity
Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).Semantic proximity
Advancing Non-Small Cell Lung Cancer Treatment: A Case Series on Pemetrexed Intrathecal Chemotherapy Monitored Through Circulating Tumor DNA in Cerebrospinal FluidSemantic proximity
High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancerSemantic proximity
Combined intrathecal therapy via Ommaya reservoir and whole-brain radiotherapy improves survival in EGFR-mutant NSCLC patients with leptomeningeal metastases: a real-world cohort study.Semantic proximity
Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study.Semantic proximity
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone.Semantic proximity
Treatment and survival of analysis in patients with leptomeningeal metastasis from lung cancerSemantic proximity
Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review.Semantic proximity
High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer.Semantic proximity
Select a neighboring publication to make it the new centre.